2025
Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety
Bahouth F, Chutko B, Sholy H, Hassanain S, Zaid G, Radzishevsky E, Fahmwai I, Hamoud M, Samnia N, Khoury J, Dobrecky-Mery I. Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety. Medicines 2025, 12: 13. PMID: 40407605, PMCID: PMC12194868, DOI: 10.3390/medicines12020013.Peer-Reviewed Original ResearchAcute coronary syndromeCoronary syndromeAntiplatelet drugsCardiovascular deathComposite endpoint of cardiovascular deathAdmitted with acute coronary syndromeEndpoint of cardiovascular deathTreated with ticagrelorTreated with prasugrelSingle-center studyRetrospective observational studyRecurrent cardiac eventsDual antiplatelet drugsReal-world treatmentPercutaneous coronary interventionBARC classificationSignificant bleedingPrasugrel groupPrimary endpointP2Y12 inhibitorsNo significant differenceACS patientsCardiac eventsComposite endpointPrasugrel
2022
Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study
Nakazaki M, Oka S, Magota H, Kiyose R, Onodera R, Ukai R, Kataoka-Sasaki Y, Sasaki M, Honmou O. Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study. Journal Of Stroke And Cerebrovascular Diseases 2022, 31: 106520. PMID: 35523052, DOI: 10.1016/j.jstrokecerebrovasdis.2022.106520.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsPlatelet aggregation testCardioembolic strokePlatelet aggregationFXa inhibitorsOral anticoagulantsStroke patientsPharmacological differencesAdenosine diphosphateAggregation testConcurrent antiplatelet therapyIschemic stroke patientsCardioembolic stroke patientsOnset of symptomsResults Six patientsLight transmission aggregometryFactor Xa inhibitorsAntiplatelet therapySecondary preventionSix patientsAntiplatelet drugsAtrial fibrillationAntiplatelet effectXa inhibitorsDabigatran
2021
Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy
Farsky PS, White J, Al-Khalidi HR, Sueta CA, Rouleau J, Panza J, Velazquez E, O'Connor C, Investigators W, Dabrowski R, Djokovic L, Drazner M, Haddad H, Ali I, Keltai M, Naik A, Sopko G, Golba K, Andersson B, Carson P, Kukulski T. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. Journal Of Thoracic And Cardiovascular Surgery 2021, 164: 1890-1899.e4. PMID: 33610365, PMCID: PMC8260609, DOI: 10.1016/j.jtcvs.2020.12.094.Peer-Reviewed Original ResearchConceptsOptimal medical therapyCoronary artery bypassMedical therapyArtery bypassIschemic cardiomyopathyCause mortalityIschemic Heart Failure (STICH) trialVentricular ejection fraction 35Improved long-term survivalEjection fraction 35Angiotensin receptor blockersHeart Failure TrialLower cardiovascular mortalityMultivariable Cox modelOutcomes of patientsVentricular ejection fractionCoronary artery diseaseLong-term outcomesLong-term survivalSurgical revascularizationReceptor blockersCardiovascular mortalityAntiplatelet drugsArtery diseaseEjection fraction
2020
Secondary prevention of cardiovascular disease in China
Lu J, Zhang L, Lu Y, Su M, Li X, Liu J, Zhang H, Nasir K, Masoudi F, Krumholz H, Li J, Zheng X. Secondary prevention of cardiovascular disease in China. Heart 2020, 106: 1349-1356. PMID: 31980439, DOI: 10.1136/heartjnl-2019-315884.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAlcohol DrinkingCardiovascular DiseasesChinaFemaleHealthy LifestyleHeart Disease Risk FactorsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPlatelet Aggregation InhibitorsRisk AssessmentRisk Reduction BehaviorSecondary PreventionSex FactorsSmoking CessationTime FactorsTreatment OutcomeConceptsSecondary prevention drugsIschemic heart diseaseCardiovascular diseasePrevention drugsIschemic strokeSecondary preventionAntiplatelet drugsCardiac Events Million Persons ProjectHistory of IHDMillion Persons ProjectSecondary prevention therapiesPopulation subgroupsMultivariable mixed modelsPublic health programsCommunities of ChinaCurrent smokersCurrent useMedication usePrevention therapyMultivariable analysisChina PatientHeart diseaseCurrent drinkersHealth programsDrugs
2013
Perioperative management of antiplatelet therapy
Oprea AD, Popescu WM. Perioperative management of antiplatelet therapy. British Journal Of Anaesthesia 2013, 111: i3-i17. PMID: 24335397, DOI: 10.1093/bja/aet402.Peer-Reviewed Original ResearchConceptsCardiovascular thrombotic eventsAntiplatelet agentsAntiplatelet medicationsThrombotic eventsPerioperative antiplatelet managementFirst-line therapyPreferred therapeutic strategyNovel antiplatelet drugsRisk stratification analysesDifferent pharmacological propertiesAntiplatelet therapyCardiovascular eventsPerioperative managementSurgical bleedingAntiplatelet drugsAntiplatelet managementTherapeutic pathwaysTherapeutic strategiesStratification analysisInterventional proceduresPerioperative teamPharmacokinetic propertiesPharmacological propertiesMajor causeMedications
2010
Use of Antithrombotic Medications Among Elderly Ischemic Stroke Patients
Lichtman JH, Naert L, Allen NB, Watanabe E, Jones SB, Barry LC, Bravata DM, Goldstein LB. Use of Antithrombotic Medications Among Elderly Ischemic Stroke Patients. Circulation Cardiovascular Quality And Outcomes 2010, 4: 30-38. PMID: 21098780, PMCID: PMC3073519, DOI: 10.1161/circoutcomes.109.850883.Peer-Reviewed Original ResearchConceptsDeep vein thrombosis prophylaxisElderly ischemic stroke patientsIschemic stroke patientsThrombosis prophylaxisAntithrombotic medicationSkilled nursing facilitiesEligible patientsAntithrombotic therapyIschemic strokeAtrial fibrillationStroke patientsNursing facilitiesPatients ages 85 yearsSecondary stroke preventionAge 85 yearsRates of receiptLow treatment ratesRate of treatmentAntiplatelet medicationsStroke preventionEffect of agePatient agePatient characteristicsAntiplatelet drugsMedicare fee
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply